Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Indivior Pharmaceuticals Inc
INDV
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $5.0B
$40.03
▼ -0.55%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$14.93 - $42.81
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 161.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Market-leading buprenorphine franchise with established brand recognition and physician relationships
- Proprietary extended-release formulations (SUBLOCADE monthly injection) reducing dosing burden and improving patient compliance
- Regulatory moat with FDA approvals and exclusivity protections for core products
- Strategic partnerships with biotech firms (ADDEX, Alar Pharmaceuticals, Click Therapeutics, Aelis Farma) accelerating pipeline innovation
- Focused expertise in addiction medicine and underserved therapeutic areas with high unmet medical needs
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Positive revenue trend
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Hot
+32.1% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying INDV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 22, 2026
APR 30, 2026
Reported EPS of $0.96 vs $0.64 consensus (+50.0% surprise). Revenue of $317.0M vs $272.8M expected (+16.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+50.0%
Next: Apr 22, 2026
Revenue trend · last 8Q
—
—
+2%
-6%
+1%
+2%
+20%
+19%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$299.0M
$307.0M
$299.0M
$266.0M
$302.0M
$314.0M
$358.0M
$317.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
28.1%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · Jun 18, 2026